Introduction: Very Low birth weight is associated with serious neonatal morbidity. Biologic factors are major determinants in their outcome. We analysed the effect of birth-weight, gestation, sex and intrauterine growth in the mortality and morbidity profile of VLBW babies during the neonatal period. Methodology: This is a cross sectional retrospective observational study from April-2012 to August-2014. Baseline demographics, disease features of 97 VLBW babies were analyzed. Results: Survival at discharge was 91.75%. There was significant difference in need of ventilation, surfactant, Apnea, ROP, IVH >/= Grade-II, Culture-negative Sepsis among all gestational subgroups. Survival increased as gestation advanced. Maximum decrease in mortality has occurred beyond 28 weeks. Maximum odds difference in need of ventilation, BPD was noted around 28 weeks. Major difference in HS-PDA, IVH, NEC were noted around 30 weeks. Significant difference in need of surfactant, apnea and anemia was observed around 32 weeks. Major decrease in HMD, Hyperbirubinemia and sepsis were identified around 34 weeks. Analysing intrauterine growth, Significant difference in Need of ventilation, surfactant use, IVH, NEC, Anemia and death was noted between AGA and SGA. Analysing birth weight wise, Survival improved as birth-weight increased. There was significant difference in HS-PDA and IVH in all birth-weight subgroups. Maximum decrease in death was noted in babies >1000g. Maximum odds difference in BPD, Apnea, Hyperbilirubinemia, IVH, Anemia, ROP and culture negative sepsis occured around 800g. Major difference in HMD, NEC, Culture positive sepsis was observed around 1000g. Significant odds difference in HS-PDA occurred around 1200g. Maximum decrease in need of surfactant and ventilation was noted around 1400g. Conclusion: There was no difference between male and female in survival or morbidities. Survival improved with advancing Gestation, Intrauterine growth and Birth-weight. Analysing intrauterine growth, Significant difference in Need of ventilation, surfactant, IVH, NEC, Anemia and death was noted between AGA and SGA. Significant variations in morbidity profile were noted among birth weight and gestational age subgroups.
Introduction: Neonatal Sepsis is commonly associated with thrombocytopenia. Objective: To assess the prevalence and course of thrombocytopenia in culture positive and culture negative neonatal sepsis in comparison to normal newborns. Methods: This is a retrospective case analysis of 533 neonates between January-2012 to December-2014. The parameters examined were Baseline Platelet Count, Change In Platelet Count, (Baseline Platelet Count-Change In Platelet Count)/ Baseline Platelet Count, Platelet Nadir, Incidence, Duration & Severity of Thrombocytopenia. Statistical Analysis: All data were collected in validated preformatted proforma sheet & analysed using appropriate statistical methods. Results: Among 533 neonates, 21.2% had Culture negative sepsis, 9.75% had culture positive sepsis & 69.04% had no sepsis. The prevalence of early onset sepsis was 17.44% & late onset sepsis was 13.50%. About 24.76% babies had thrombocytopenia; 9.56% had mild thrombocytopenia, 10.13% had moderate & 5.06% had severe thrombocytopenia. Late onset sepsis was associated with significant thrombocytopenia. Culture positive sepsis had significant drop in platelets with lower platelet nadir, higher incidence, more severe & prolonged thrombocytopenia compared to culture negative sepsis & normal neonates. Conclusion: There are quantitative differences in the platelet response to neonatal sepsis, particularly to culture positive sepsis. Hematological changes in platelet count induced by culture proven and culture negative neonatal sepsis can be used to make an early diagnosis and prompt management of neonatal sepsis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.